Skip to main content
Premium Trial:

Request an Annual Quote

People in the News: Vincent Calvez, Diane Descamps, Jacques Reynes, Mark Wainberg, Brett Begemann, Gregory Weaver

Premium

Theradiag has named four members of its newly formed scientific advisory board who will help the company develop a microRNA-based diagnostic for characterizing HIV tropism.

Members of the SAB include Vincent Calvez, a virologist at Pitie Salpetriere Hospital in Paris; Diane Descamps, a researcher at Paris-Diderot University who specializes in HIV resistance; Jacques Reynes, a professor at the University Hospital of Montpellier who studies HIV/AIDS; and Mark Wainberg, director of the McGill AIDS Center at Quebec Jewish General Hospital.


Monsanto has named Brett Begemann as its new president and COO. He most recently served as the company's president and chief commercial officer.

In his expanded role, Begemann will continue to oversee Monsanto's worldwide sales and operations, but will now handle corporate affairs, as well.


Atossa Genetics has appointed Gregory Weaver to its board of directors and named him as a member of its audit committee.

Weaver previously served as CFO of Sirna Therapeutics prior to its acquisition by Merck.

The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.